OncotypeDX® is the most frequently used multigene assay when deciding about treatment recommendations in breast cancer patients after surgery
Within the international oncology congress IMPAKT 2014, that was organised by ESMO organisation in Brussel in May 2014, Professor Matti Aapro presented the MAGIC survey results. This survey was focused on the usage of multigene assays in oncology and overall almost 900 clinicians in 52 countries completed this survey.
From the amount of all 875 clinicians, 485 (55%) of them responded that they use some of the genomic assays when deciding about treatment recommendations for newly diagnosed patients with hormone receptor positive, HER2 negative, invasive breast cancer. Among the most frequently used tests according to the participating clinicians were OncotypeDX® (78%) followed by Mammaprint (34%). The results of this survey also showed that all the other tests are used in less than 10% of the cases. Countries that use these multigene assays for breast cancer the most are Greece (91% of clinicians) and Germany (89% of clinicians). And also in these two countries the most frequently used assay is OncotypeDX®. This representative survey with almost 900 participating clinicians in many European countries confirmed the dominant position of the OncotypeDX® assay when deciding about treatment recommendations for newly diagnosed patients with hormone receptor positive, HER2 negative, invasive breast cancer. OncotypeDX® is also the only assay of this kind that is incorporated in all major international guidelines for clinical practice (NCCN, ASCO, ESMO, St. Gallen....) within their recommendation on diagnosis and treatment of breast cancer.
You can find more information about this survey on the encologypro.esmo.org web pages here.